Gem Aromatics FY26: Sequential recovery in Q4, but the Dahej ramp is still a work in progress

Gem Aromatics ended Q4 FY26 with a clear sequential improvement, even as the year-on-year comparison stayed weak. On a standalone basis, Q4 revenue came in at INR 112.2 crore, up 34% quarter-on-quarter, supported by improving customer engagement, better volumes, and improved price realization. Gross margin improved to 23.4% from 18.4% in Q3, and EBITDA margin moved up to 13.4% from 9.1%.

On a consolidated basis, Q4 revenue stood at INR 110.4 crore, up 40% QoQ, with EBITDA of INR 15.7 crore and EBITDA margin at 14.2%. The key disconnect came at the bottom line. Consolidated PAT was only INR 1 crore in Q4, largely because depreciation rose to INR 9 crore after capitalization of the Dahej greenfield capex. Cash PAT, however, improved to INR 10 crore from INR 3.7 crore in Q3, indicating that operating momentum improved even if accounting profits were held back.

The larger context remained challenging. For FY26, consolidated revenue declined to INR 366.5 crore from INR 504.0 crore in FY25. EBITDA fell to INR 40.8 crore from INR 88.5 crore. PAT dropped to INR 1.4 crore from INR 53.4 crore. Management attributed the pressure primarily to tariff-related uncertainty impacting mint exports, combined with the transition phase as the company capitalized and began commissioning new capacities at Dahej.

What changed in Q4: demand, realizations, and mix

Management described Q4 as a quarter where the operating environment improved, supported by better clarity on US tariffs and improving trade conditions. This helped volumes and realizations, and in turn brought gross margins and EBITDA margins closer to normalized levels.

The company also pointed to encouraging traction in non-mint categories, particularly clove and its derivatives. While it did not disclose quarterly segment mix, the FY26 segment snapshot in the investor presentation indicated that mint still dominated the portfolio, but diversification was visible.

The key operational point from the call was utilization. Management stated that at the standalone business level, utilization was about 80% or slightly above in the prior year, but dipped to about 60% to 65% in FY26 due to mint export weakness.

Dahej: the strategic bet and why depreciation matters

The company’s biggest multi-year initiative is the Dahej greenfield project under its wholly owned subsidiary Krystal Ingredients Private Limited. The investor presentation highlighted about INR 270 crore of investment, with about INR 260 crore already incurred and substantially capitalized by Q4 FY26. This capitalization drove a sharp increase in depreciation at the consolidated level.

Dahej is positioned as a high-value specialty manufacturing platform. The company highlighted a total capacity of 10,871 MTPA across four segments, including a 500 MTPA cooling agents unit using vapor-phase technology.

Commercial production of GEM Cool 5 and Safranal commenced on 26 February 2026. Management also highlighted that the entire facility went live in April 2026, but declined to provide a near-term utilization guidance given geopolitical uncertainty.

Importantly, the company linked the Dahej capex to revenue potential during the Q and A. It stated that it expects an asset turn of about 3 to 3.5 times, implying peak potential revenue of about INR 800 crore from the new Dahej unit. While not a profitability guidance, this is a useful anchor for understanding the scale management is targeting.

Phenol derivatives: ready plant, delayed ramp

A key near-term swing factor is phenol derivatives. The company stated the plant is production-ready and catalyst preparation is complete, but phenol supply disruptions and price spikes due to geopolitical issues have delayed production timelines.

Management explained that many suppliers called force majeure or delayed shipments, pushing demand into the spot market and driving prices higher. Given the nature of continuous operations and the need for consistent raw material availability, the company decided not to kick-start production at elevated and fluctuating phenol prices. It indicated that it would be more comfortable starting once prices stabilize or find an equilibrium.

This matters because phenol derivatives are part of the intended shift toward advanced chemistry products like Anisole, Anethole, MEHQ, Guaiacol, and 4-MAP. In FY26, this vertical contributed only INR 5 crore, about 1% of revenue.

Cooling agents and citral chemistry: forward integration and new molecules

Cooling agents are being positioned as a forward integration from the mint vertical. Management said the decision was driven by demand from oral care customers and an adjacent opportunity in confectionery applications such as chewing gum.

It also stated that cooling agents are tariff-exempt for India to the US, which supports export competitiveness, particularly in a global environment where tariffs have distorted trade flows.

Citral chemistry is another new area. The investor presentation noted in-house R and D process know-how for Safranal and Damascone, with installed capacity of 51 MTPA. Safranal commercial production began in February 2026.

Governance, compliance, and ESG signals

The company highlighted multiple compliance milestones. Dahej completed second-stage audits for FSSC 22000 Version 6, GHP, HACCP, ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018. Management also said the plant is undergoing multiple customer and certification audits, and expects a significant portion of qualification activity to complete over the next two quarters, supporting potential CMO and CDMO opportunities.

On ESG, Silvassa received an EcoVadis Platinum sustainability rating. While this is not a financial driver in the short term, it can support long-term customer engagement in export markets that increasingly demand traceability and responsible manufacturing.

Key takeaways for investors

Gem Aromatics closed FY26 in a transition phase. Q4 showed sequential recovery in revenue, margins, and cash PAT, indicating that demand and realizations improved once tariff uncertainty eased.

At the same time, FY26 results were weighed down by a sharp year-on-year decline in revenue, lower utilization, and a significant jump in depreciation after Dahej capex capitalization. The company has chosen not to guide FY27, citing geopolitical uncertainty and raw material volatility, especially for phenol.

For FY28, management reiterated a target of about INR 1,100 crore consolidated turnover with EBITDA margins of 16% to 18%. Execution over the next few quarters will depend on how quickly Dahej utilization ramps, how soon phenol derivatives stabilize and start contributing meaningfully, and whether export conditions remain supportive for the mint and cooling agents portfolio.